Keywords: lilly, xanomeline, eli, selective, muscarinic, m1, agonist

Lilly's Xanomeline

Article | 17 July 1995

Print This

Eli Lilly's selective muscarinic M1 agonist xanomeline has shown efficacy in the treatment of Alzheimer's disease in a Phase II ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in